Prime Inks Trio of Value-Based Pacts for Migraine Drugs
In recent weeks, Prime Therapeutics LLC has entered into not one, not two, but three value-based contracts with drug manufacturers for a trio of migraine medicines. The PBM owned by 18 Blue Cross and Blue Shield plans tells AIS Health that it identified migraine treatments as a key target for value-based pacts — which tie reimbursement to outcomes and costs — because of how the market for such drugs is shaping up.
“Prime focused on the migraine class because there were new opportunities to bring value associated with both new chronic and acute migraine [drugs] to the class, more expensive than existing therapeutics,” says Kelly McGrail-Pokuta, vice president of trade relations and strategy and chief trade relations officer at Prime. “With new products there is no real-world evidence, so by implementing value-based contracts, Prime and the manufacturers are given the opportunity to look at data.”
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Senior Editor, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile